https://www.selleckchem.com/pr....oducts/aticaprant.ht
Body weight-normalized CL/F decreased with age. Cancer status and sex did not have significant effects on CL/F and Vd/F. Simulations were conducted to select starting doses of dalteparin that would rapidly achieve therapeutic anti-Xa levels. These simulations suggested that the recommended starting doses of dalteparin administered subcutaneously in pediatric patients of different age cohort groups for treatment of VTE were 150 IU/kg every 12 hours (1 month to less then 2 years), 125 IU/kg every 12 hours (≥2 to less then 8 years), and
Like
Comment
Share
